Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty.
about
Mathematical Modelling to Guide Drug Development for Malaria EliminationHeterogeneity, mixing, and the spatial scales of mosquito-borne pathogen transmissionThe Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line TherapiesContrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis."Every drug goes to treat its own disease…" - a qualitative study of perceptions and experiences of taking anti-retrovirals concomitantly with anti-malarials among those affected by HIV and malaria in Tanzania.Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children.Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model.Naturally acquired immune responses to malaria vaccine candidate antigens MSP3 and GLURP in Guahibo and Piaroa indigenous communities of the Venezuelan AmazonOptimum population-level use of artemisinin combination therapies: a modelling study.A framework for assessing the risk of resistance for anti-malarials in development.Therapeutic efficacy of artemether-lumefantrine combination in the treatment of uncomplicated malaria among children under five years of age in three ecological zones in Ghana.Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach.A combined within-host and between-hosts modelling framework for the evolution of resistance to antimalarial drugsMMV in partnership: the Eurartesim® experience.Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present.The impact of heterogeneous transmission on the establishment and spread of antimalarial drug resistance.Plasmodium falciparum Polymorphisms associated with ex vivo drug susceptibility and clinical effectiveness of artemisinin-based combination therapies in Benin.Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa.Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa.malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication.Malaria medicines to address drug resistance and support malaria elimination efforts.A theoretical examination of the relative importance of evolution management and drug development for managing resistance.Putting evolution in elimination: Winning our ongoing battle with evolving malaria mosquitoes and parasites.Within-host competition can delay evolution of drug resistance in malariaThe Impact of Antimalarial Use on the Emergence and Transmission of Plasmodium falciparum Resistance: A Scoping Review of Mathematical Models
P2860
Q28067367-812AE58B-DB52-4857-8864-087BFFFA3267Q28536895-30A18452-1F83-47C2-9029-91350EAAA4E6Q28551049-E2FEC9A3-8900-4955-9F3B-CE2BE3B32AB1Q34677891-BAB4C330-9587-40D6-97B4-B83589B888A9Q34996394-E7FB9102-4FD2-451F-8079-BEA3764DBD07Q35052961-D7C6EC8D-C640-4F07-B9C7-84C5A164AF4EQ35107675-6D71DAF0-0D59-44FD-9F4B-6440DA2563A0Q35812148-45773F13-69EE-497F-9B83-C199FCD02BD1Q36269820-5FA00E4D-68FC-44B4-995A-5DE1E91AAE36Q36340996-659A2E54-55EF-4E37-97B6-87239868ABEBQ36459535-45A4A2CE-0AB7-4B1E-B208-73F349790E16Q36538998-8D3AA44C-8B0C-464B-A2A5-9E13B277AF32Q36921047-9D212E34-2729-438A-BD06-1FD5DCDD4234Q36952896-4D487CB9-3789-46A1-8CE9-1201E73F4955Q37390583-1B4B3B1B-B41B-4585-89FC-0FDA98A8D364Q37396654-4349C08A-1062-491B-94C3-6D0FE9D465CAQ37544298-4D7F1EC5-9136-4689-94FB-E8135A8FD298Q38636047-09A17984-7BE6-4854-8808-6118F352A438Q39393283-072D15A4-FC39-4635-B988-02E2CF335653Q47130457-3393A963-7110-4F9F-9234-D2ACB54AABF0Q48007457-36F7A906-3C43-4140-BD5B-B79852BA803FQ51015217-64D5C052-763F-4426-9149-AC9AA0F6384BQ52595160-80A8C099-3984-4009-B38E-A8F1170BCC57Q56341998-CD26B2AD-4036-4F0B-A701-CBAFB6E60CF2Q57151906-EE93046D-6923-4683-83DA-144016656A56
P2860
Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prospective strategies to dela ...... nce: weighing the uncertainty.
@ast
Prospective strategies to dela ...... nce: weighing the uncertainty.
@en
Prospective strategies to dela ...... nce: weighing the uncertainty.
@nl
type
label
Prospective strategies to dela ...... nce: weighing the uncertainty.
@ast
Prospective strategies to dela ...... nce: weighing the uncertainty.
@en
Prospective strategies to dela ...... nce: weighing the uncertainty.
@nl
prefLabel
Prospective strategies to dela ...... nce: weighing the uncertainty.
@ast
Prospective strategies to dela ...... nce: weighing the uncertainty.
@en
Prospective strategies to dela ...... nce: weighing the uncertainty.
@nl
P2860
P356
P1433
P1476
Prospective strategies to dela ...... nce: weighing the uncertainty.
@en
P2093
F Ellis McKenzie
Ramanan Laxminarayan
P2860
P2888
P356
10.1186/1475-2875-9-217
P577
2010-07-23T00:00:00Z
P5875
P6179
1020827866